MDXGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

MIMEDX GROUP, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026

$4.38−0.05 (-1.13%)

Close on Oct 19, 2026

Market cap: $647.35M
P/E (TTM): 109.5
Dividend yield: –

Dividends

Mimedx has not reported a dividend

No dividend per share appears in Mimedx's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Mimedx's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MDXG.

Revenue growth-2.4% · median 11.8%

Gross margin78.8% · median 72.9%

Operating margin2.5% · median -5.1%

Net margin1.8% · median -13.4%

Company	Revenue	Growth
AORT	$471.47M	+16.4%
MDXG	$355.17M	-2.4%
LMAT	$262.43M	+11.8%
AXGN	$251.17M	+23.6%
TELA	$79.91M	+6.1%
RCEL	$75.63M	+1.0%

Company

Next earnings (est.): Oct 28, 2026, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 808
Held by institutions: 80.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1376339

Advertisement
300 × 250